We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
BCAX

Price
9.32
Stock movement up
+0.67 (6.11%)
Company name
Bicara Therapeutics Inc. Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
634.57M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-09-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

BCAX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open10.86
Daily high11.72
Daily low10.82
Daily Volume348K
All-time high27.07
1y analyst estimate33.00
Beta-
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date18 Nov 2025

Downside potential

Loading...
Downside potential data
BCAXS&P500
Current price drop from All-time high-57.04%-1.46%
Highest price drop-67.82%-56.47%
Date of highest drop27 Jun 20259 Mar 2009
Avg drop from high-43.56%-10.99%
Avg time to new high59 days12 days
Max time to new high233 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
BCAX (Bicara Therapeutics Inc. Common Stock) company logo
Marketcap
634.57M
Marketcap category
Small-cap
Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Employees
55
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...